HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a $36 price target.
July 16, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Pliant Therapeutics and maintained a $36 price target.
The reiteration of a Buy rating and the maintenance of a $36 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100